ArticleCancer chemotherapy and pharmacology2025

Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).

Aziz Ouerdani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.